TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06940336: A Single Arm, Multicenter, Open-label,Phase IV Clinical Study to Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients withTransthyretin Amyloid Polyneuropathy

Sponsor: Qilu Pharmaceutical Co., Ltd. · Phase: PHASE4 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,635,840

Rescue Site Savings

+$5,028,480

Unlock Full NCT06940336 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06940336 Rescue Dossier →